Canaccord Adams
http://www.canaccordadams.com/default.htmCanaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, their 225 professionals seek out emerging opportunities in their key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, their experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.
View Older Stories View More Recent Stories
-
Canaccord Downgrades Insulet (PODD) to Hold
-
Canaccord Adams Boosts Price Target On Cyberonics (CYBX) to $28.75, Following Better Results
-
Canaccord Adams Starts Delcath Systems (DCTH) at Speculative Buy
-
Canaccord Ups Price Target on Martek (MATK) from $34 to $37
-
Canaccord Starts Myriad Genetics (MYGN) at Sell; $41.50 PT
-
Canaccord Adams Boosts Price Tartet on Rubicon Tech (RBCN) to $28
-
Canaccord Adams Raises Price Target on NaviSite (NAVI) to $5.40
-
Canaccord Adams Adds Omniture (OMTR) To Best Ideas List
-
Canaccord Adams Downgrades Sonic Solutions (SNIC) to Hold
-
Canaccord Adams Downgrades Alliance Data Systems (ADS) to Hold
-
Canaccord Raises Price Target on FuelCell (FCEL) to $10
-
Color on Canaccord Coverage of Approach Resources (AREX)
-
Canaccord Reiterates Buy on Research In Motion (RIMM); $200 PT
-
Canaccord Starts Approach Resources (AREX) at Buy
-
Canaccord Raises Price Target on Goldcorp (GG) to $50; Maintains Buy
-
Canaccord Adams Reiterates Bullish View on VistaPrint (VPRT)
-
Canaccord Adams Upgrades Methanex (MEOH) to Hold
-
Canaccord Adams Boosts Price Target on Semtech (SMTC) to $20
-
Canaccord Upgrades Vivus (VVUS) to Buy
-
Canaccord Reiterates Buy on Analog Devices (ADI); $37 PT
-
Canaccord Adams Sees Bankrate (RATE) As An Attractive Takeover
-
Pharmacopeia (PCOP) Surges On Positive DARA Phase 2a Trial Data
-
Unusual 11 Mid-Day Movers 5/13: IOMI, CSIQ, FSYS, WCI, USNA Higher; NXTM, USS, CRZ, IMB Lower
-
Canaccord Adams Adds VistaPrint (VPRT) to Best Ideas List
-
Canaccord Reiterates Buy on Research In Motion (RIMM); $200 PT
-
Canaccord Adams Downgrades NxStage Medical (NXTM) to Hold
-
Canaccord Adams Downgrades Hansen Natural (HANS) to Hold
-
Canaccord Adams Said RIM's BlackBerry Bold Could Become a "Blockbuster" (RIMM)
-
Canaccord Adams Downgrades TELUS Corp (TU) to Hold
-
Color on Canaccord's Upgrade of NVIDIA (NVDA) to Buy
-
Canaccord Upgrades NVIDIA (NVDA) from Sell to Buy
-
Canaccord Adams Raises Price Target on Research In Motion (RIMM) to $200
-
Real Goods Solar (RSOL) IPO Trades Lower
-
Canaccord Positive on Pharmacopeia (PCOP) Into DARA Phase 2a Data
-
Sprint and Clearwire's WiMax Deal a Positive for NextWave (WAVE) - Canaccord
-
Canaccord Adams Cuts Price Target on Internap (INAP) to $3.80
-
Canaccord Adams Trims Price Target on Golden Star Resources (GSS) to $4
-
Real Goods Solar (RSOL) IPO Prices at $10
-
Unusual 11 Mid-Day Movers 5/6: IAR, IPHS, RAS, CRBC Higher; OMPI, IBI, DSCM, PSS Lower
-
Canaccord Adams Removed Drugstore.com (DSCM) from Best Idea List
-
Canaccord Adams Upgrades Microsoft (MSFT) to Buy
-
Canaccord Adams Boosts Ests and PT on Research In Motion (RIMM), Cites New Devices and Upgrade Cycle
-
Canaccord Adams Very Bullish On Research In Motion (RIMM), Sees A Number of Upcoming Catalysts
-
Canaccord Adams Bumps Price Target on Wright Medical (WMGI) to $38
-
Canaccord Adams Trims Price Target on Bottomline Tech (EPAY) to $13, Maintains Hold
-
Canaccord Adams Boosts Price Target on Data Domain (DDUP) to $33.25, Following Strong Q1
-
Canaccord Adams Upgrades Newfield Exploration (NFX) to Buy
-
NextWave Wireless (WAVE) Soars On Plans to Sell US Wireless Spectrum
-
Canaccord Adams Raises Price Tgt on Quicksilver (KWK) to $50
-
Canaccord Adams upgrades Rackable Systems (RACK) to Buy

